CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
NDA 20-066 / S-016

Name: Nicorette (4 mg Nicotine Polacrilex) Gum

Sponsor: GlaxoSmithKline Consumer Healthcare

Approval Date: April 23, 2004
## Reviews / Information Included in this Review

<table>
<thead>
<tr>
<th>Review Type</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Approvable Letter(s)</td>
<td>X</td>
</tr>
<tr>
<td>Approved Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Labeling Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Clinical Pharmacology / Biopharmaceutics Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative Document(s)</td>
<td>X</td>
</tr>
<tr>
<td>Correspondence</td>
<td>X</td>
</tr>
</tbody>
</table>
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 20-066 / S-016

APPROVAL LETTER
NDA 20-066/S-016

GlaxoSmithKline Consumer Healthcare
Attention: Zinatara A. Manji
Associate, Regulatory Affairs
1500 Littleton Road
Parsippany, NJ 07054-3884

Dear Ms. Manji:

Please refer to your supplemental new drug application dated November 26, 2003, received December 2, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Nicorette® (4 mg nicotine polacrilex) gum.


This supplemental new drug application proposes a new mint flavored uncoated gum.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (carton label submitted April 6, 2004, and Users Guide submitted March 12, 2004) and must be formatted in accordance with the requirements of 21 CFR 201.66.

We remind you to remove the word “New” from the carton label after 6 months of marketing.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Laura Shay, Regulatory Project Manager, at (301) 827-2274.

Sincerely yours,

\{See appended electronic signature page\}

Charles Ganley, MD  
Deputy Director  
Division of Over the Counter Drug Products  
Office of Drug Evaluation V  
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
----------------------
Charles Ganley
4/23/04 10:40:29 AM
APPLICATION NUMBER:
NDA 20-066 / S-016

APPROVABLE LETTER(S)
NDA 20-066/S-016

GlaxoSmithKline Consumer Healthcare
Attention: Zinatara A. Manji
Associate, Regulatory Affairs
1500 Littleton Road
Parsippany, NJ 07054-3884

Dear Ms. Manji:

Please refer to your supplemental new drug application dated November 26, 2003, received December 2, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Nicorette® 4 mg (nicotine polacrilex) gum.

We also acknowledge receipt of your February 5, 2004, March 1, 2004, March 12, 2004 and March 29, 2004 submissions.

This supplemental new drug application proposes a new mint flavored uncoated gum.

We have completed the review of this application and it is approvable. Before the application may be approved, however, you must address the following deficiencies:

1. Results from the bioequivalence study provided in this supplement has failed to demonstrate in vivo bioequivalence. Our position is that failure of bioequivalence is due to the difficulties in establishing equivalent chewing patterns between the current and reformulated products as a result of varying amounts of nicotine extracted under the test conditions. Therefore, we recommend using the gum release rate tester ("chewing machine") to test in vitro bioequivalence. An in vitro apparatus such as this can provide both a consistent chewing force and rate of chewing that cannot be achieved readily in vivo and would thus be more reproducible, and allow for the comparison of products in a standardized manner.

2. Submit draft labeling that incorporates the labeling changes provided in the March 12, 2004 amendment.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

Under 21 CFR 314.102(d), you may request a meeting or telephone conference with this division to discuss what further steps need to be taken before the application may be approved.

This product may be considered to be misbranded under the Federal Food, Drug, and Cosmetic Act if it is marketed with this change before approval of this supplemental application.
At this time, the final specifications for — mint uncoated Nicorette® 4 mg gum product is acceptable from a pharmacology and toxicology perspective. However, you should ————-. to positive genetic toxicology reports in the literature and the potential conversion to nitrosocompounds.

If you have any questions, call Laura Shay, Regulatory Project Manager, at (301) 827-2274.

Sincerely yours,

[See appended electronic signature page]

Charles Ganley, MD
Deputy Director
Division of Over the Counter Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

-------------------------------
Charles Ganley
4/2/04 03:16:06 PM
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 20-066 / S-016

APPROVED LABELING
Dear Ms. Manji:

We acknowledge receipt of your November 4, 2004, submission containing final printed labeling in response to our April 23, 2004, letters approving your supplemental new drug applications for Nicorette® uncoated (2mg nicotine polacrilex) gum, and Nicorette® uncoated (4mg nicotine polacrilex) gum.

We have reviewed the labeling that you submitted in accordance with our April 23, 2004, letter and we find it acceptable.

In addition, we recommend the following revisions be made at the time of next printing. Submit revised labeling reflecting these changes in the next annual report.

1. Under the subheading “Ask a doctor before use if you have,” in the Warnings section under Drug Facts, insert the following statement as the first bullet:
   - a sodium-restricted diet

2. In the User Guide, on page 4 under the subheading “Ask a doctor before use if you have,” insert the following statement as the first bullet:
   - a sodium-restricted diet

3. Remove the direction “Bite into a piece of Nicorette gum and chew” located on the inside top carton panel. This statement is inconsistent with the directions in Drug Facts and in the user guide.

We remind you that the word “NEW” must be deleted from the principal display panel six months after introduction into the OTC market place.
If you have any questions, call Laura Shay, Regulatory Project Manager, at 301-827-2274.

Sincerely,

{See appended electronic signature page}

Curtis Rosebraugh M.D., M.P.H.
Deputy Director
Division of Over-the-Counter Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research
Nicorette 2mg, Soft and Sweet Uncoated Mint, 110 Pieces
Front Panel
Top

To remove the gum, tear off single unit.

Peel off backing, starting at corner with loose edge.

Push gum through foil.

**FREE INDIVIDUALIZED STOP SMOKING PROGRAM**

**COMMITTED QUITTERS**

**VISIT COMMITTEDQUITTERS.COM**

(TM)

(To Enroll See Details Inside)

**To Increase Your Success in Quitting:**
1. You must be motivated to quit.
2. Use Enough - Chew at least 9 pieces of Nicorette per day during the first six weeks.
3. Use Long Enough - Use Nicorette for the full 12 weeks.
4. Use with a support program as directed in the enclosed User’s Guide.

Bottom

Nicorette®

mint

OPEN HERE

Nicorette 2mg, Soft and Sweet Uncoated Mint, 110 Pieces

Top and Bottom Panels
**Drug Facts**

**Active ingredient (in each chewing piece)**

Nicotine polatex (equal to 2mg nicotine)........Stop smoking aid

**Purpose**

- Reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking

**Use**

- If you are pregnant or breast-feeding, only use this medicine as the advice of your healthcare provider. Smoking can seriously harm your child. Try to stop smoking without using any nicotine replacement medicine. This medicine is believed to be safer than smoking. However, the risks to your child from this medicine are not fully known.

- Do not use
  - if you continue to smoke, chew tobacco, use snuff, or use a nicotine patch or other nicotine-containing products

**Warnings**

- Ask a doctor before use if you have
  - Heart disease, recent heart attack, or irregular heartbeat. Nicotine can increase your heart rate.
  - High blood pressure not controlled with medication. Nicotine can increase blood pressure.
  - Stomach ulcer or diabetes

- Ask a pharmacist before use if you are
  - Using a non-nicotine smoking aid
  - Taking prescription medicine for depression or asthma. Your prescription dose may need to be adjusted.

- Stop use and ask a doctor if
  - Irregular heartbeat or palpitations occur
  - You get symptoms of nicotine overdose such as nausea, vomiting, diziness, diarrhea, weakness, and rapid heartbeat

- Keep out of reach of children and pets. Pieces of nicotine gum may have enough nicotine to make children and pets sick. Wrap used pieces of gum in paper and throw away in the trash. In case of overdose, get medical help or contact a Poison Control Center right away.

**Drug Facts (continued)**

**Directions**

- If you are under 18 years of age, ask a doctor before use
- Before using this product, read the enclosed User's Guide for complete directions and other important information
- Stop smoking completely when you begin using the gum
- If you smoke 25 or more cigarettes a day, use 4mg nicotine gum
- If you smoke less than 25 cigarettes a day, use according to the following 12 week schedule:

<table>
<thead>
<tr>
<th>Weeks</th>
<th>1 to 6</th>
<th>Weeks 7 to 9</th>
<th>Weeks 10 to 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 piece every 1 to 2 hours</td>
<td>1 piece every 2 to 4 hours</td>
<td>1 piece every 4 to 8 hours</td>
<td></td>
</tr>
</tbody>
</table>

- Nicotine gum is a medicine and must be used a certain way to get the best results
- Chew the gum slowly until it tingles. Then park it between your cheek and gum. When the tingle is gone, begin chewing again, until the tingle returns.
- Repeat this process until most of the tingle is gone (about 30 minutes)
- Do not eat or drink for 15 minutes before chewing the nicotine gum, or while chewing a piece
- To improve your chances of quitting, use at least 9 pieces per day for the first 6 weeks
- If you experience strong or frequent cravings, you may use a second piece within the hour. However, do not continuously use one piece after another since this may cause you to hiccup, heartburn, nausea, or other side effects.
- Do not use more than 24 pieces a day
- It is important to complete treatment. Stop using the nicotine gum at the end of 12 weeks. If you still feel the need to use nicotine gum, talk to your doctor.

**Other information**

- Store at 20 - 25°C (68 - 77°F)
- Protect from light

**Inactive ingredients**

- Acetaminophen, saccharin, potassium, gum base, magnesium oxide, menthol, peppermint oil, sodium bicarbonate, sodium carbonate, xylitol

**Questions or comments?** Call 1-800-419-4766 weekdays (10:00 a.m. - 4:30 p.m. EST)

Manufactured by Pharmacia AB, Stockholm, Sweden for GlaxoSmith Kline Consumer Healthcare, L.P.
Moon Township, PA 15108
© 2004 GlaxoSmithKline

Nicorette 2mg, Soft and Sweet Uncoated Mint, 110 Pieces

Back Panel
Bite+Park™

Nicorette isn't like ordinary gum. It's a medicine and must be used a certain way to get the best results.

**Bite**

Bite into a piece of Nicorette gum and chew very slowly several times. Stop chewing when you notice a peppery taste, or a slight tingling in your mouth.

**Park**

Park the Nicorette piece between your cheek and gum, and leave it there. When the peppery taste or tingle is almost gone (in about a minute), start to chew a few times slowly again. When the taste or tingle returns, stop again. Park the piece again in a different place in your mouth.

Repeat this process until most of the tingle is gone (about 30 minutes). Read carton and enclosed User's Guide for complete directions and other important information.

©2003 GlaxoSmithKline Read and follow label directions.

110ct Inside Copy
Top

To remove the gum, tear off single unit. Peel off backing, starting at corner with loose edge. Push gum through foil.

TO INCREASE YOUR SUCCESS IN QUITTING:
1. You must be motivated to quit.
2. Use Enough - Chew at least 9 pieces of Nicorette per day during the first six weeks.
3. Use Long Enough - Use Nicorette for the full 12 weeks.
4. Use with a support program as directed in the enclosed User's Guide.

Bottom

Nicorette® mint

OPEN HERE

Nicorette 4mg, Soft and Sweet Mint, 110 Pieces
Top and Bottom Panels
**Drug Facts**

**Active ingredient (in each chewing piece)**

| Purpose | Nicotine polacrilex (equal to 4mg nicotine) |

**Use**

- reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking

**Warnings**

If you are pregnant or breast-feeding, only use this medicine on the advice of your health care provider. Smoking can adversely harm your child. Try to stop smoking without using any nicotine replacement medicine. This medicine is believed to be safe than smoking. However, the risks to your child from this medicine are not fully known.

Do not use:
- If you continue to smoke, chew tobacco, use snuff, or use a nicotine patch or other nicotine containing products.

Ask a doctor before use if you have:
- Heart disease, recent heart attack, or irregular heartbeat. Nicotine can increase your heart rate.
- High blood pressure not controlled with medication. Nicotine can increase blood pressure.
- Stomach ulcer or diabetes.

Ask a doctor or pharmacist before use if you are:
- Using a non-nicotine stop smoking drug.
- Taking prescription medicine for depression or asthma. Your prescription dose may need to be adjusted.

Stop use and ask a doctor if:
- Mouth, teeth or jaw problems occur.
- Irregular heartbeat or palpitations occur.
- You get symptoms of nicotine overdose such as nausea, vomiting, diarrhea, weakness and rapid heartbeat.

**Keep out of reach of children and pets.** Pieces of nicotine gum may have enough nicotine to make children and pets sick. Wrap unused pieces of gum in paper and throw away in the trash. In case of overdose, get medical help or contact a Poison Control Center right away.

**Other information**

- Store at 20 - 25°C (68 - 77°F).
- Protect from light.

**Inactive ingredients**

| ascorbic acid, potassium, D&C yellow #10 Al Lake, gum base, magnesium oxide, menthol, peppermint oil, sodium carbonate, xylitol |

**Questions or comments?**
call 1-800-419-4768 weekdays (10:00 a.m. - 4:30 p.m. EST)

---

**Nicorette 4mg, Soft and Sweet Mint, 110 Pieces**

**Back Panel**
Nicorette 4mg, Soft and Sweet Mint, 110 Pieces
Side Panels
Bite+Park™

Nicorette isn't like ordinary gum. It's a medicine and must be used a certain way to get the best results.

**Bite**

Bite into a piece of Nicorette gum and chew very slowly several times. Stop chewing when you notice a peppery taste, or a slight tingling in your mouth.

**Park**

Park the Nicorette piece between your cheek and gum, and leave it there. When the peppery taste or tingle is almost gone (in about a minute), start to chew a few times slowly again. When the taste or tingle returns, stop again. Park the piece again (in a different place in your mouth).

Repeat this process until most of the tingle is gone (about 30 minutes). Read carton and enclosed User's Guide for complete directions and other important information.

©2003 GlaxoSmithKline Read and follow label directions.

110ct Inside Copy
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Curtis Rosebraugh

5/10/05 01:24:24 PM
APPLICATION NUMBER:
NDA 20-066 / S-016

LABELING REVIEW(S)
Stock Keeping Unit: Nicorette (nicotine polacrilex) uncoated gum, 4 mg, 110 ct carton

Information Included in the Submission

<table>
<thead>
<tr>
<th>Content of Submission</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. A cover letter stating that the submission includes new labeling in the Drug Facts format for the drug product and shelf keeping unit(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. A table of contents or index</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. The most recent approved labeling *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. A representation of the proposed labeling, including any outserts, panel extensions, or other graphical or package techniques intended to be used with the product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Information on formatting, text style, and text size as illustrated in 64 FR 13254 at 293</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Additional labeling submitted under 21 CFR 314.70(c) or (d) since the last approved labeling should be included in the submission with the date of submission referenced and how they were submitted (e.g. annual report, pending supplement).

The information provided is adequate for review: Yes

Background

This review is based on GlaxoSmithKline’s April 6, 2004 submission of NDA 20066/SCF-016(AZ) for New Mint flavored uncoated Nicorette® 4 mg gum. This submission is in response to the Agency’s Approvable Letter, dated April 2, 2004, for the new mint uncoated gum formulation. The submission addresses the deficiencies noted in the Approvable letter. The sponsor has included and highlighted the proposed label changes in draft printed labeling for the carton (see attachment 1). The sponsor states that all labeling revisions will be reflected in final printed labeling for Nicorette —mint Uncoated 2 mg and 4 mg gum. The draft labeling is almost identical to the Mint Nicorette® gum products, with the exception of changes related to flavor. Unless otherwise noted, the reviewer’s comments and recommendations refer to the labeling for the new mint flavored uncoated Nicorette® 4 mg, 110ct size carton.

Reviewer’s Recommendations

The following recommendations on the proposed labeling can be conveyed to the sponsor. See attachment 1

1. Carton Back, Directions.
   a. Bullet 2. The words "" are changed to read: "User’s Guide."
   
   This change is acceptable

   b. Bullet 13, first sentence. The sentence "" is changed to read:
   
   "it is important to complete treatment. Stop using the nicotine gum at the end of 12 weeks."
   
   This change is acceptable.
Inform the sponsor that the label can be approved.

Mary S. Robinson, M.S.
Regulatory Review Chemist, HFD-560

Helen Cothran, B.S.
Team Leader, HFD-560

cc: HFD-170:
HFD-560: CGanley/CRosebraugh/HCothran/DShetty/LShay/MRobinson
R/D: MRobinson
F/T: MRobinson
5 page/s of draft labeling was/were removed from this portion of the review

4/21/2004 LABELING REVIEW

20-0460/5-016
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Mary Robinson
4/22/04 05:23:51 PM
INTERDISCIPLINARY

Helen Cothran
4/23/04 09:55:14 AM
INTERDISCIPLINARY
Stock Keeping Unit: N/A

Information Included in the Submission

<table>
<thead>
<tr>
<th>Content of Submission</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. A cover letter stating the submission includes new labeling in the Drug Facts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>format for the drug product and shelf keeping unit(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. A table of contents or index</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. The most recent approved labeling *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. A representation of the proposed labeling, including any outserts, panel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>extensions, or other graphical or package techniques intended to be used with</td>
<td></td>
<td></td>
</tr>
<tr>
<td>the product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Additional labeling submitted under 21 CFR 314.70(c) or (d) since the last approved labeling should be included in the submission with the date of submission referenced and how they were submitted (e.g. annual report, pending supplement).

The information provided is adequate for review: Yes

Background

This review is based on GlaxoSmithKline’s March 12, 2004 submissions of NDA 20066/SLR-016 BL for Nicorette® New Mint flavored 4 mg uncoated gum. This submission includes modifications to the User’s Guide for the new uncoated Mint gum formulation. The sponsor has included the revised User’s Guide in draft printed labeling. (See attachment 1). The User’s Guide is almost identical to the User’s Guide in the other Mint Nicorette® gum products, with the exception of changes related to flavor and the changes listed below. The sponsor states that the changes to the carton labeling will be reflected in the final printed labeling for this supplement.

Reviewer’s Recommendations

The following recommendation on the changes made in the User’s Guide can be conveyed to the sponsor. See attachment 1.

   a. The sponsor has moved the heading "TIPS TO MAKE QUITTING EASIER" from before the sentence "STOP USING NICORETTE AT THE END OF WEEK 12" (see page 12) to page 13, bullet 4.

   This change is acceptable.
b. Page 13, following bullet 1, the following information is added:

"Talk to your doctor if you:
  • still feel the need to use Nicorette at the end of week 12
  • start using Nicorette again after stopping
  • start smoking again"

This change is acceptable.

Inform the sponsor that the above changes to the user's guide are acceptable.

The sponsor did not submit carton labeling in this amendment # 3, but stated that the changes to the carton labeling submitted in NDA 20066/S-017 will be reflected in the final printed labeling for this supplement (S-016).

Remind the sponsor that the carton label change recommended for NDA 20066/S-017 is as follows:

On the carton back, under directions revise bullet 13, first sentence * "it is important to complete treatment. Stop using the nicotine gum at the end of 12 weeks."

Mary S. Robinson, M.S.
Regulatory Review Chemist, HFD-560

Helen Cothran, B.S.
Team Leader, HFD-560

cc: HFD-170:
HFD-560: CGanley/CRosebraugh/HCothran/DShetty/LShay/MRobinson
R/D: MRobinson
F/T: MRobinson
Nicorette®

nicotine polacrilex gum
2mg and 4mg User's Guide

HOW TO USE NICORETTE TO HELP YOU QUIT SMOKING.

Copyright ©2001 GlaxoSmithKline Consumer Healthcare, L.P.
• Not for sale to those under 18 years of age.
• Proof of age required.
• Not for sale in vending machines or from any source where proof of age cannot be verified.
KEYS TO SUCCESS.

1) You must really want to quit smoking for Nicorette® to help you.
2) You can greatly increase your chances for success by using at least 9 to 12 pieces every day when you start using Nicorette. See page 11.
3) You should continue to use Nicorette as explained in this User's Guide for 12 full weeks.
4) Nicorette works best when used together with a support program — See page 3 for details.
5) If you have trouble using Nicorette, ask your doctor or pharmacist or call GlaxoSmithKline at 1-800-419-4766 weekdays (10:00 am - 4:30 pm EST)
SO YOU CONGRATULATIONS.
DECIDED Your decision to
TO QUIT: stop smoking is an
important one.
That's why you've made the right
choice in choosing Nicorette gum.
Your own chances of quitting
smoking depend on how much
you want to quit, how strongly
you are addicted to tobacco, and
how closely you follow a quitting
program like the one that comes
with Nicorette.
QUITTING SMOKING IS HARD!
If you've tried to
quit before and
haven't succeeded,
don't be discour-
gaged! Quitting isn't easy. It takes
time, and most people try a few
times before they are successful.
The important thing is to try again
until you succeed.

Copyright © 2001 GlaxoSmithKline Consumer Healthcare, LP
This User's Guide will give you support as you become a nonsmoker. It will answer common questions about Nicorette and give tips to help you stop smoking, and should be referred to often.

WHERE TO GET HELP: You are more likely to stop smoking by using Nicorette with a support program that helps you break your smoking habit. There may be support groups in your area for people trying to quit. Call your local chapter of the American Lung Association, American Cancer Society or American Heart Association for further information. Toll free phone numbers are printed on the Wallet Card on the back of this User's Guide.

If you find you cannot stop smoking or if you start smoking again after using Nicorette, remember breaking this addiction doesn't happen overnight. You may want to talk to a health care professional who can help you improve your chances of quitting the next time you try Nicorette or another method.

LET'S GET ORGANIZED: Your reason for quitting may be a combination of concerns about health, the effect of smoking on your appearance, and pressure from your family and friends to stop smoking. Or maybe you're
concerned about the dangerous
effect of second-hand smoke on
the people you care about.
All of these are good reasons. You
probably have others. Decide
your most important reasons, and
write them down on the wallet
card inside the back cover of this
User's Guide. Carry this card with
you. In difficult moments, when
you want to smoke, the card will
remind you why you are quitting.

WHAT
YOU'RE UP
AGAINST

Smoking is addictive in two
ways. Your need
for nicotine has
become both physical and
mental. You must overcome both
addictions to stop smoking. So
while Nicorette will lessen your
body's physical addiction to
nicotine, you've got to want to
quit smoking to overcome the
mental dependence on cigarettes.
Once you've decided that you're
going to quit, it's time to get
started. But first, there are some
important warnings you should
consider.

SOME
IMPORTANT
WARNINGS.

This product is
only for those
who want to
stop smoking.
If you are pregnant or breast-
feeding, only use this medicine
on the advice of your health
care provider. Smoking can
seriously harm your child. Try to
stop smoking without using any
nicotine replacement medicine.
This medicine is believed to be safer than smoking. However, the risks to your child from this medicine are not fully known.

Do not use:
- If you continue to smoke, chew tobacco, use snuff, or use a nicotine patch or other nicotine containing products.

Ask a doctor before use if you have:
- Heart disease, recent heart attack, or irregular heartbeat. Nicotine can increase your heart rate.
- High blood pressure not controlled with medication. Nicotine can increase your blood pressure.
- Stomach ulcer or diabetes

Ask a doctor or pharmacist before use if you are:
- Using a non-nicotine stop smoking drug
- Taking a prescription medicine for depression or asthma. Your prescription dose may need to be adjusted.

Stop use and ask a doctor if:
- Mouth, teeth or jaw problems occur
- Irregular heartbeat or palpitations occur
- You get symptoms of nicotine overdose such as nausea, vomiting, dizziness, diarrhea, weakness and rapid heartbeat

Keep out of reach of children and pets. Pieces of nicotine gum may have enough nicotine to make children and pets sick. Wrap used pieces of gum in paper and throw away in the trash. In case of...
overdose, get medical help or contact a Poison Control Center right away.

**LET'S GET STARTED.** 

Becoming a non-smoker starts today. First, check that you bought the right starting dose. If you smoke 25 or more cigarettes a day, use 4 mg nicotine gum. If you smoke less than 25 cigarettes a day, use 2 mg nicotine gum. Next, read through the entire User's Guide carefully. Then, set your personalized quitting schedule. Take out a calendar that you can use to track your progress, and identify four dates, using the stickers in the center of this User's Guide:

---

**STEP 1. (Weeks 1-6). Your quit date (and the day you'll start using Nicorette gum).**

Choose your quit date (it should be soon). This is the day you will quit smoking cigarettes entirely and begin using Nicorette to satisfy your cravings for nicotine. For the first six weeks, you'll use a piece of Nicorette every hour or two. Be sure to follow the directions starting on pages 9 and 11. Place the Step 1 stickers on this date.

**STEP 2. (Weeks 7 to 9). The day you'll start reducing your use of Nicorette.**

After six weeks, you'll begin gradually reducing your Nicorette usage to one piece every two to four hours. Place the Step 2 stickers on this date.

---

Copyright ©2001 GlaxoSmithKline Consumer Healthcare, LP
stickers on this date (the first day of week seven).
STEP 3. (Weeks 10-12). The day you'll further reduce your use of Nicorette.
Nine weeks after you begin using Nicorette, you will further reduce your nicotine intake by using one piece every four to eight hours.
Place the Step 3 sticker on this date (the first day of week ten). For the next three weeks, you'll use a piece of Nicorette every four to eight hours.
End of treatment: The day you'll complete Nicorette therapy.
Nicorette should not be used for longer than twelve weeks. Identify the date thirteen weeks after the date you chose in Step 1, and place the "EX-SMOKER" sticker on your calendar.

PLAN Because smoking is AHEAD an addiction, it is not easy to stop. After you've given up cigarettes, you will still have a strong urge to smoke. Plan ahead NOW for these times, so you're not defeated in a moment of weakness. The following tips may help:
- Keep the phone numbers of supportive friends and family members handy.
- Keep a record of your quitting process. Track the number of Nicorette pieces you use each day, and whether you feel a craving for cigarettes. In the event that you slip, immediately stop smoking and resume your
quit attempt with the Nicorette program.

• Put together an Emergency Kit that includes items that will help take your mind off occasional urges to smoke. Include cinnamon gum or lemon drops to suck on, a relaxing cassette tape, and something for your hands to play with, like a smooth rock, rubber band, or small metal balls.

• Set aside some small rewards, like a new magazine or a gift certificate from your favorite store, which you’ll "give" yourself after passing difficult hurdles.

• Think now about the times when you most often want a cigarette, and then plan what else you might do instead of smoking. For instance, you might plan to take your coffee break in a new location, or take a walk right after dinner, so you won’t be tempted to smoke.

**HOW NICORETTE GUM WORKS.**

Nicorette’s sugar-free chewing gum provides nicotine to your system — they work as a temporary aid to help you quit smoking by reducing nicotine withdrawal symptoms. Nicorette provides a lower level of nicotine to your system than cigarettes, and allows you to gradually do away with your body’s need for nicotine.
Because Nicorette does not contain the tar or carbon monoxide of cigarette smoke, it does not have the same health dangers as tobacco. However, it still delivers nicotine, the addictive part of cigarette smoke. Nicotine can cause side effects such as headache, nausea, upset stomach, and dizziness.

**HOW TO USE**

If you are under 18 years of age, ask a doctor before use.

Before you can use Nicorette correctly, you have to practice! That sounds silly, but it isn't. Nicorette isn't like ordinary chewing gum. It's a medicine, and must be chewed a certain way to work right. Chewed like ordinary gum, Nicorette won't work well and can cause side effects. An overdose can occur if you chew more than one piece of Nicorette at the same time, or if you chew many pieces one after another. Read all the following instructions before using Nicorette. Refer to them often to make sure you're using Nicorette gum correctly. If you chew too fast, or do not chew correctly, you may get hiccups, heartburn, or other stomach problems. Don't eat or drink for 15 minutes before using Nicorette, or while chewing a piece. The effectiveness of Nicorette may be reduced by some foods and drinks, such as coffee, juices, wine or soft drinks.
1) Stop smoking completely before you start using Nicorette.
2) To reduce craving and other withdrawal symptoms, use Nicorette according to the dosage schedule on page 11.
3) Chew each Nicorette piece very slowly several times.
4) Stop chewing when you notice a peppery taste, or a slight tingling in your mouth. (This usually happens after about 15 chews, but may vary from person to person.)
5) "PARK" the Nicorette piece between your cheek and gum, and leave it there.
6) When the peppery taste or tingling is almost gone (in about a minute), start to chew a few times slowly again. When the taste or tingling returns, stop again.
7) Park the Nicorette piece again (in a different place in your mouth).
8) Repeat steps 3 to 7 (chew, chew, park) until most of the nicotine is gone from the Nicorette piece (usually happens in about half an hour; the peppery taste or tingling won't return.)
9) Wrap the used Nicorette piece in paper and throw away in the trash.
PLACE THESE STICKERS ON YOUR CALENDAR:

**STEP 1**
1 piece every 1 to 2 hours
AT THE BEGINNING OF WEEK #1
(QUIT DATE)

**STEP 2**
1 piece every 2 to 4 hours
AT THE BEGINNING OF WEEK #7

**STEP 3**
1 piece every 4 to 8 hours
AT THE BEGINNING OF WEEK #10

**EX-SMOKER**
12 WEEKS AFTER QUIT DATE
The following chart lists the recommended usage schedule for Nicorette:

<table>
<thead>
<tr>
<th>Weeks 1 to 6</th>
<th>Weeks 7 to 9</th>
<th>Weeks 10 to 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 piece every 1 to 2 hours</td>
<td>1 piece every 2 to 4 hours</td>
<td>1 piece every 4 to 8 hours</td>
</tr>
</tbody>
</table>

DO NOT USE MORE THAN 24 PIECES PER DAY.

To improve your chances of quitting, use at least 9 pieces of Nicorette a day. If you experience strong or frequent cravings you may use a second piece within the hour. However, do not continuously use one piece after another, since this may cause you hiccups, heartburn, nausea or other side effects.

**HOW TO REDUCE YOUR NICORETTE USAGE**

The goal of using Nicorette is to slowly reduce your dependence on nicotine. The schedule for using Nicorette will help you reduce your nicotine craving gradually as you reduce and then stop your use of Nicorette. Here are some tips to help you cut back during each step and then stop using Nicorette.
• After a while, start chewing each Nicorette piece for only 10 to 15 minutes, instead of half an hour. Then, gradually begin to reduce the number of pieces used.
• Or, try chewing each piece for longer than half an hour, but reduce the number of pieces you use each day.
• Substitute ordinary chewing gum for some of the Nicorette pieces you would normally use. Increase the number of pieces of ordinary gum as you cut back on the Nicorette pieces.
• Check how well you've reduced your daily usage of Nicorette in Weeks 10 to 12. You should only be using about 3 to 5 pieces a day. Get ready to stop.

STOP USING NICORETTE AT THE END OF WEEK 12. The following tips may help you with stopping Nicorette Gum at the end of 12 weeks.
• Set a stop date.
• Use the same number of pieces of confectionery gum or mints as you were using Nicorette per day. At the times when you have an urge to use Nicorette, use a strong flavored gum or mint such as cinnamon or peppermint.
Reduce the number of pieces of gum or mints you use by one piece per day until you do not need to use any gum or mints.

Talk to your doctor if you:
- still feel the need to use Nicorette at the end of week 12
- start using Nicorette again after stopping
- start smoking again

**TIPS TO MAKE QUITTING EASIER**

Within the first few weeks of giving up smoking, you may be tempted to smoke for pleasure, particularly after completing a difficult task, or at a party or bar. Here are some tips to help you through the important first stages of becoming a non-smoker:

- On Your Quit Date:
  - Ask your family, friends and coworkers to support you in your efforts to stop smoking.
  - Throw away all your cigarettes, matches, lighters, ashtrays, etc.
  - Keep busy on your quit day.
  - Exercise. Go to a movie. Take a walk. Get together with friends.
  - Figure out how much money you'll save by not smoking. Most ex-smokers can save more than $1,000 a year.
  - Write down what you will do with the money you save.
  - Know your high risk situations and plan ahead how you will deal with them.
- Keep Nicorette gum near your bed, so you'll be prepared for any nicotine cravings when you wake up in the morning.
- Visit your dentist and have your teeth cleaned to get rid of the tobacco stains.

Right after Quitting:
- During the first few days after you've stopped smoking, spend as much time as possible at places where smoking is not allowed.
- Drink large quantities of water and fruit juices.
- Try to avoid alcohol, coffee and other beverages you associate with smoking.

- Remember that temporary urges to smoke will pass, even if you don't smoke a cigarette.
- Keep your hands busy with something like a pencil or a paper clip.
- Find other activities which help you relax without cigarettes.

- Swim, jog, take a walk, play basketball.
- Don't worry too much about gaining weight. Watch what
you eat, take time for daily exercise, and change your eating habits if you need to.
• Laughter helps. Watch or read something funny.

WHAT TO EXPECT
Your body is now coming back into balance. During the first few days after you stop smoking, you might feel edgy and nervous and have trouble concentrating. You might get headaches, feel dizzy and a little out of sorts, feel sweaty or have stomach upset. You might even have trouble sleeping at first. These are typical withdrawal symptoms that will go away with time. Your smoker's cough will get worse before it gets better. But don’t worry, that’s a good sign. Coughing helps clear the tar deposits out of your lungs.

After A Week Or Two.
By now you should be feeling more confident that you can handle those smoking urges. Many of your withdrawal symptoms have left by now, and you should be noticing some positive signs: less coughing, better breathing and an improved sense of taste and smell, to name a few.
After A Month, you probably have the urge to smoke much less often now. But urges may still occur, and when they do, they are likely to be powerful ones that come out of nowhere. Don't let them catch you off guard. Plan ahead for these difficult times.

Concentrate on the ways non-smokers are more attractive than smokers. Their skin is less likely to wrinkle. Their teeth are whiter, cleaner. Their breath is fresher. Their hair and clothes smell better. That cough that seems to make even a laugh sound more like a rattle is a thing of the past. Their children and others around them are healthier, too.

What To Do About Relapse. What should you do if you slip and start smoking again? The answer is simple. A lapse of one or two or even a few cigarettes has not spoiled your efforts! Discard your cigarettes, forgive yourself and try again.

If you start smoking again, keep your box of Nicorette for your next quit attempt. If you have taken up regular smoking again, don't be discouraged. Research shows that the best thing you can do is to try again. The important thing is to learn from your last attempt.

• Admit that you've slipped, but don't treat yourself as a failure.
• Try to identify the "trigger" that
caused you to slip, and prepare a better plan for dealing with this problem next time.

* Talk positively to yourself – tell yourself that you have learned something from this experience.

* Make sure you used Nicorette gum correctly over the full 12 weeks to reduce your craving for nicotine.

* Remember that it takes practice to do anything, and quitting smoking is no exception.

**WHEN THE STRUGGLE IS OVER.**

Once you've stopped smoking, take a second and pat yourself on your back. Now do it again. You deserve it.

Remember now why you decided to stop smoking in the first place. Look at your list of reasons. Read them again. And smile.

Now think about all the money you are saving and what you'll do with it. All the non-smoking places you can go, and what you might do there. All those years you may have added to your life, and what you'll do with them. Remember that temptation may not be gone forever. However, the hard part is behind you so look forward with a positive attitude, and enjoy your new life as a non-smoker.

**QUESTIONS & ANSWERS.**
1. How will I feel when I stop smoking and start using Nicorette?
You'll need to prepare yourself for some nicotine withdrawal symptoms. These begin almost immediately after you stop smoking, and are usually at their worst during the first three or four days. Understand that any of the following is possible:
- craving for cigarettes
- anxiety, irritability, restlessness, mood changes, nervousness
- drowsiness
- trouble concentrating
- increased appetite and weight gain
- headaches, muscular pain, constipation, fatigue.

Nicorette can help provide relief from withdrawal symptoms such as irritability and nervousness, as well as the craving for nicotine you used to satisfy by having a cigarette.

2. Is Nicorette just substituting one form of nicotine for another?
Nicorette does contain nicotine. The purpose of Nicorette is to provide you with enough nicotine to help control the physical withdrawal symptoms so you can deal with the mental aspects of quitting. During the 12 week program, you will gradually reduce your nicotine intake by switching to fewer pieces each day. Remember, don't use Nicorette together with nicotine.
patches or other nicotine containing products.

3. Can I be hurt by using Nicorette?
For most adults, the amount of nicotine in the gum is less than from smoking. Some people will be sensitive to even this amount of nicotine and should not use this product without advice from their doctor (see page 4). Because Nicorette is a gum-based product, chewing it can cause dental fillings to loosen and aggravate other mouth, tooth and jaw problems. Nicorette can also cause hiccups, heartburn and other stomach problems especially if chewed too quickly or not chewed correctly.

4. Will I gain weight?
Many people do tend to gain a few pounds the first 8-10 weeks after they stop smoking. This is a very small price to pay for the enormous gains that you will make in your overall health and attractiveness. If you continue to gain weight after the first two months, try to analyze what you're doing differently. Reduce your fat intake, choose healthy snacks, and increase your physical activity to burn off the extra calories.

5. Is Nicorette more expensive than smoking?
The total cost of Nicorette for the twelve week program is about equal to what a person who smokes one and a half packs of
cigarettes a day would spend on cigarettes for the same period of time. Also, use of Nicorette is only a short-term cost, while the cost of smoking is a long-term cost, because of the health problems smoking causes.

6. What if I slip up?
Discard your cigarettes, forgive yourself and then get back on track. Don’t consider yourself a failure or punish yourself. In fact, people who have already tried to quit are more likely to be successful the next time.

GOOD LUCK!
WALLET CARD

My most important reasons to quit smoking are:

_______________________
_______________________
_______________________
_______________________

Copyright © 2001 GlaxoSmithKline Consumer Healthcare, L.P.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
Mary Robinson
4/1/04 10:59:48 AM
INTERDISCIPLINARY

Helen Cothran
4/1/04 12:32:21 PM
INTERDISCIPLINARY
Division of OTC Drug Labeling Review
HFD-560

NDA # 20-066
Drug Product: Nicorette
Sponsor: GlaxoSmithKline

# of Stock Keeping Units in Submission: 4
Submission Date: November 26, 2003 and February 5, 2004
Review Date: March 2, 2004

Type of Submission: NDA 20066/SCF-016 and NDA 20066/SCF-016BL
Reviewer: Mary S. Robinson

Stock Keeping Unit: Nicorette (nicotine polacrilex) uncoated gum, 4 mg, 110 ct carton,

Information Included in the Submission

<table>
<thead>
<tr>
<th>Content of Submission</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. A cover letter stating that the submission includes new labeling in the Drug Facts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>format for the drug product and shelf keeping unit(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. A table of contents or index</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. The most recent approved labeling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. A representation of the proposed labeling, including any outserts, panel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>extensions, or other graphical or package techniques intended to be used with the</td>
<td></td>
<td></td>
</tr>
<tr>
<td>product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Information on formatting, text style, and text size as illustrated in 64 FR 13254</td>
<td></td>
<td></td>
</tr>
<tr>
<td>at 293</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Additional labeling submitted under 21 CFR 314.70(c) or (d) since the last approved labeling should be included in the submission with the date of submission referenced and how they were submitted (e.g. annual report, pending supplement).

The information provided is adequate for review: Yes

Background
This review is based on GlaxoSmithKline's November 26, 2003 and February 5, 2004 submissions of NDA 20066/SCF-016 for Nicorette® New Mint flavored 4 mg uncoated gum. These submissions introduce the new uncoated Mint gum formulation and contain proposed modifications to the current Nicorette® Mint drug product labeling for the carton and User's Guide. The sponsor has included the proposed label changes in full color draft printed labeling for the Cartons and User Guide (see attachment 1). The labeling is almost identical to the Mint Nicorette® gum products, with the exception of changes related to flavor and the changes listed below. Unless otherwise noted, the reviewer's comments and recommendations refer to the labeling for the mint flavored uncoated Nicorette® 4 mg 110ct, size cartons, CD cover, CD label and CD transcript (in February 5, 2004 submission), Blister, User's Guide and inside top panel.

Reviewer's Recommendations

The following recommendations on the proposed labeling can be conveyed to the sponsor. See attachment 1

1. Carton Back, Directions.
   a. Bullet 13, first sentence.
For emphasis, make two sentences as follows:
"It is important to complete treatment. Stop using the nicotine gum at the end of 12 weeks."

   Under "STOP USING NICORETTE AT THE END OF WEEK 12," bullet 4, page 13, the following information is added:
   - Talk to your doctor if you still feel the need to use Nicorette, 
     ————————————————————
     ————————————————————
     ————————————————————
     ————————————————————
     start smoking again.

This tip is long and confusing. For clarity, break it into shorter phrases as follows:
- Talk to your doctor if you:
  - still feel the need to use Nicorette at the end of week 12
  - start using Nicorette again after stopping
  - start smoking again

3. Delete the word “New” from the label after the first 6 months of OTC marketing.

Inform the sponsor that the label cannot be approved until the changes noted above are made.

Mary S. Robinson, M.S.
Regulatory Review Chemist, HFD-560

Helen Cothran, B.S.
Team Leader, HFD-560

cc: HFD-170:
    HFD-560: CGanley/CRosebraugh/HCothran/DShetty/LShay/MRobinson
    R/D: MRobinson
    F/T: MRobinson
40 page/s of draft labeling was/were removed from this portion of the review
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
Mary Robinson
4/1/04 09:56:10 AM
INTERDISCIPLINARY

Helen Cothran
4/1/04 12:30:27 PM
INTERDISCIPLINARY
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 20-066 / S-016

CLINICAL PHARMACOLOGY / BIOPHARMACEUTICS REVIEW(S)
Clinical Pharmacology/Biopharmaceutics Review

Nicotine Polacrilex 2 and 4mg gum
NDA 18-612 SCF-034 (2mg)
NDA 20-066 SCF-016 (4mg)
Nicorette Uncoated Gum
Reviewer: E.D. Bashaw, Pharm.D.
Glaxo SmithKline
Parsippany, NJ
Submission Date:
11/26/03
2/24/04

Review of In Vitro Release Data/Flavor Change

Background

These supplements have been submitted to allow for a both a change in flavor of Nicorette gum from citrus to mint, and to allow for both coated and un-coated forms of the mint flavor.

Previously this sponsor had submitted the results of in vivo bioequivalency studies for comparison of these products to the currently marketed Nicorette® gum. When the bioequivalence criteria were not met, the Sponsor had tried to adjust the data for the remaining nicotine and had recalculated the 95% confidence intervals for comparison of the products. This approach for determining bioequivalence was considered not acceptable, and the Agency recommended that the sponsor provide an in vitro comparison of the products by using an apparatus also known as the “chewing machine”. An in vitro apparatus such as this can provide standardized conditions such as consistent chewing force and rate of chewing, and allow a more reliable in vitro comparison of these products. In vitro data collected in this manner complement in vivo comparison of these products.

This sponsor had developed previously a “chewing machine” in which six independent sets of metal teeth could be set at pre-determined rates to maintain a fixed amount of force to chew medicated gums in separate water baths. The water baths then would be sampled over time for release testing purposes. The results plotted over time can be analyzed for similarity by graphical methods as well as by application of the F2 testing approach as described in the FDA Guidance on Immediate Release Solid Oral Dosage Forms.

Methods

In these studies, nicotine release profiles were determined from the original Nicorette (currently marketed) product (2- and 4-mg) and the New Mint flavored coated and uncoated products (2- and 4-mg). A total of 6 individual gums from 3 batches of each of the test and reference formulations were evaluated. The instrumental settings (chewing frequency, jaw distance, temperature) and testing media were identical for all
formulations. Samples were withdrawn from the cells after 2, 5, 10, 20 and 30 minutes of mastication.

**Lots Tested**

*Test*
Nicorette 2mg Mint flavored (also referred to as S&S)* uncoated batches:
DB 616, DB 617, DB 618
Nicorette 4mg Mint flavored (also referred to as S&S) uncoated batches:
DD 705, DD 706, DD 707

Nicorette 2mg Mint flavored (also referred to as S&S) coated batches:
EE 8001, EE 8002, EE 8003
Nicorette 4mg Mint flavored (also referred to as S&S) coated batches:
EE 8102, EE 8103, EE 8105

*[Note that Nicorette New Mint was referred to as “S&S” in previous development work.]*

*Reference*
Nicorette 2mg Orange (also referred to as citrus) batches: DD 560, DD 561, DD 562
Nicorette 4mg Orange (also referred to as citrus) batches: BK623A, DA533A, DD 585A

The in vitro release profiles, as determined in the "chewing" apparatus, were also compared by the $f_2$ (similarity factor) approach that is described in the FDA CDER Guidance for Immediate Release Solid Oral Dosage forms. Following application of the $f_2$ approach, values greater than 50 are considered to be indicative of similar profiles.

**Results**

Overall the results from in vitro testing of different lots of Nicorette gum gave reproducible results across both strengths and coatings of the gum. Over a 30 min test period the "chewing" apparatus/machine was able to extract out, on average, approximately 99% of the labeled amount of nicotine (see tables 1-4, attached). In terms of F2 testing, the following mean results were obtained:

<table>
<thead>
<tr>
<th>Comparator</th>
<th>F2 factor relative to reference product</th>
</tr>
</thead>
<tbody>
<tr>
<td>2mg uncoated</td>
<td>67</td>
</tr>
<tr>
<td>4mg uncoated</td>
<td>66</td>
</tr>
<tr>
<td>2mg coated</td>
<td>65</td>
</tr>
<tr>
<td>4mg coated</td>
<td>74</td>
</tr>
</tbody>
</table>

In vitro nicotine release profiles for the proposed Nicorette formulations and the currently marketed product are similar. For illustration purposes, profiles for the proposed 2- and 4-mg mint flavored uncoated Nicorette product are presented in this
review and the in vitro release data for both coated and uncoated proposed Nicorette products and the currently marketed Nicorette product are presented in the attached Tables 1-4.

Mean Nicotine Release Rates 2 and 4mg uncoated gum

Nicotine In-vitro release

Nicotine In-vitro release

Nicorette 2mg S&S
Nicorette 2mg Orange

Nicorette 4 mg S&S
Nicorette 4 mg Orange
Conclusions

The results of the F2 testing along with a visual examination of the data reveal that the change in flavor or the coating of the products have had little if any effect on the release of nicotine from the polacrilex matrix that is the Nicorette gum. These data complement the in vivo data submitted earlier and support that the proposed products are similar to the currently marketed Nicorette gum.

Recommendation

Based on the information presented in this supplement, the Division of Pharmaceutical Evaluation-III has no objection to the proposed formulation changes/line extensions for a mint flavored coated and a mint flavored uncoated 2 and 4 mg Nicorette product.

Dennis Bashaw, Pharm.D.
HFD-540/550/560
PK Review Team Leader

Secondary Review: Arzu Selen, Ph.D., Deputy Director, DPE-III

APPEARS THIS WAY ON ORIGINAL
Table 1. The compiled nicotine in-vitro release results from three batches of the test gum Nicorette 2 mg S&S and three batches of the reference gum Nicorette 2 mg Orange.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Study No: A02228 Nicorette 2mg S&amp;S (% of label claim)</th>
<th>Study No: A02177 Nicorette 2mg Orange (% of label claim)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Study No: A02228 Nicorette 2mg S&amp;S (% of label claim)</td>
<td>Study No: A02177 Nicorette 2mg Orange (% of label claim)</td>
</tr>
<tr>
<td></td>
<td>DB 616</td>
<td>DB 517</td>
</tr>
<tr>
<td>Average SD</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>RSD</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>5</td>
<td>45.16</td>
<td>47.13</td>
</tr>
<tr>
<td>Average SD</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>RSD</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>10</td>
<td>74.37</td>
<td>76.92</td>
</tr>
<tr>
<td>Average SD</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>RSD</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>20</td>
<td>94.32</td>
<td>93.29</td>
</tr>
<tr>
<td>Average SD</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>RSD</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>30</td>
<td>100.01</td>
<td>97.44</td>
</tr>
<tr>
<td>Average SD</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>RSD</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>
### TABLE 2

Table 1. The compiled nicotine in-vitro release results from three batches of the test gum Nicorette 2 mg S&S coated and three batches of the reference gum Nicorette 2 mg Orange/Citrus

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Study No: A03277 Nicorette 2 mg S&amp;S coated (% of label claim)</th>
<th>Study No: A02177 Nicorette 2 mg Orange/Citrus (% of label claim)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EE8001 EE8002 EE8003</td>
<td>DD560 DD561 DD562</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Average 15.31 15.41 15.12 15.3</td>
<td>Average 13.50 14.89 13.96 14.2</td>
</tr>
<tr>
<td></td>
<td>SD 2 2 1</td>
<td>SD 1 1 1</td>
</tr>
<tr>
<td></td>
<td>RSD 11 11 10</td>
<td>RSD 7 10 7</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Average 45.67 47.20 47.60 46.8</td>
<td>Average 41.56 42.74 41.26 41.9</td>
</tr>
<tr>
<td></td>
<td>SD 2 3 2</td>
<td>SD 3 2 3</td>
</tr>
<tr>
<td></td>
<td>RSD 2 7 4</td>
<td>RSD 7 6 6</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Average 73.08 74.12 76.59 74.8</td>
<td>Average 68.08 70.04 67.42 68.5</td>
</tr>
<tr>
<td></td>
<td>SD 2 3 1</td>
<td>SD 3 1 1</td>
</tr>
<tr>
<td></td>
<td>RSD 3 5 2</td>
<td>RSD 4 2 5</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Average 92.88 92.22 94.99 93.4</td>
<td>Average 88.88 91.91 87.80 89.6</td>
</tr>
<tr>
<td></td>
<td>SD 1 4 2</td>
<td>SD 3 2 5</td>
</tr>
<tr>
<td></td>
<td>RSD 1 4 2</td>
<td>RSD 4 2 5</td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Average 100.47 98.54 100.55 99.9</td>
<td>Average 97.29 101.29 95.80 98.1</td>
</tr>
<tr>
<td></td>
<td>SD 1 4 2</td>
<td>SD 5 3 4</td>
</tr>
<tr>
<td></td>
<td>RSD 1 4 2</td>
<td>RSD 5 3 4</td>
</tr>
</tbody>
</table>
TABLE 3

Table 2. The compiled nicotine in-vitro release results from three batches of the test gum Nicorette 4 mg S&S and three batches of the reference gum Nicorette 4 mg Orange.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Study No: A02376 Nicorette 4mg S&amp;S (% of label claim)</th>
<th>Study No: A02376 Nicorette 4mg Orange (% of label claim)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>DD705 DD706 DD707</td>
<td>DA533A BK823A DD585A</td>
</tr>
<tr>
<td></td>
<td>Average 17.12 15.67 11.22 14.0</td>
<td>Average 11.80 11.72 10.85 11.5</td>
</tr>
<tr>
<td></td>
<td>SD 1 0 0</td>
<td>SD 1 1 0</td>
</tr>
<tr>
<td></td>
<td>RSD 8 3 4</td>
<td>RSD 9 10 3</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Average 56.65 48.73 47.29 50.9</td>
<td>Average 47.34 50.06 44.24 47.2</td>
</tr>
<tr>
<td></td>
<td>SD 3 3 1</td>
<td>SD 2 2 2</td>
</tr>
<tr>
<td></td>
<td>RSD 4 6 2</td>
<td>RSD 4 3 4</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Average 87.73 82.01 81.95 83.9</td>
<td>Average 78.31 82.98 77.47 79.9</td>
</tr>
<tr>
<td></td>
<td>SD 3 3 2</td>
<td>SD 3 2 2</td>
</tr>
<tr>
<td></td>
<td>RSD 3 4 2</td>
<td>RSD 3 2 2</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Average 102.61 99.38 99.21 100.4</td>
<td>Average 95.88 102.71 97.30 98.6</td>
</tr>
<tr>
<td></td>
<td>SD 2 3 3</td>
<td>SD 4 2 2</td>
</tr>
<tr>
<td></td>
<td>RSD 2 3 3</td>
<td>RSD 4 2 2</td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Average 106.67 104.65 105.32 105.5</td>
<td>Average 101.24 108.06 103.15 104.1</td>
</tr>
<tr>
<td></td>
<td>SD 1 4 2</td>
<td>SD 2 2 2</td>
</tr>
<tr>
<td></td>
<td>RSD 1 4 2</td>
<td>RSD 2 2 2</td>
</tr>
</tbody>
</table>
Table 2. The compiled nicotine in-vitro release results from three batches of the test gum Nicorette 4 mg S&S coated and three batches of the reference gum Nicorette 4 mg Orange/Citrus.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Study No: A03277 Nicorette 4 mg S&amp;S coated (% of label claim)</th>
<th>Study No: A02376 Nicorette 4 mg Orange/Citrus (% of label claim)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EE8102</td>
<td>EE8103</td>
</tr>
<tr>
<td>2</td>
<td>16.98</td>
<td>16.31</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>13</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>53.41</td>
<td>53.02</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>82.55</td>
<td>82.86</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>98.37</td>
<td>99.19</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>104.05</td>
<td>104.55</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
______________________________________
Dennis Bashaw
4/22/04 06:59:48 PM
BIOPHARMACEUTICS

Arzu Selen
4/22/04 07:12:03 PM
BIOPHARMACEUTICS
Clinical Pharmacology and Biopharmaceutics Review

Nicotine Polacrilex Gum
Nicorette®
Reviewer: E.D. Bashaw, Pharm.D.
NDA 18-612 s-034 & -037, 2mg
NDA 20-066 s-016 & -019, 4mg
Glaxo Smith Kline
Submission Date:
11/26/03
2/20/04

Review of NDA Supplement

Background
This review covers two NDAs and a total of four supplements divided between the 2mg nicotine gum (NDA 18-612 s-034 & -037) and the 4mg nicotine gum (NDA 20-066 s-016 & -019). Specifically these supplements deal with a minor reformulation issue, namely the addition of mint flavoring and an outer coating. The sponsor had been advised previously that an in vitro study would be possible under the provisions of 21 CFR 320.22(d)(4), however, the sponsor elected to perform two in vivo biostudies instead. As the 2 and 4mg nicotine gums are under separate NDAs, the results from these trials were filed separately as a supplement to each NDA.

NDA 18-612 S-034 (2mg)
NDA 20-066 S-016 (4mg)
These supplemental New Drug Applications (sNDA) are being submitted to acquire Over-the-Counter (OTC) marketing approval for a new mint flavor Nicorette (nicotine polacrilex) 2 and 4 mg gum. This new formulation is also referred to by the sponsor as: Nicorette ---- mint Uncoated 2 and 4 mg gum, throughout this application.

An in vivo bioequivalence study (Study No. NICSOS-9132-003) entitled, “Bioequivalence between Two New Nicotine Gums (2 and 4 mg) and Nicorette® Gum (2 and 4 mg) in an Open, Randomized, Crossover, Phase I Study in Healthy Smoking Volunteers was included in these supplements. This study was designed to assess the bioequivalence between the original flavor 2 mg gum and the new mint flavor 2 mg variant, which is the subject of this sNDA. The study also compares the 4 mg original flavor gum and the 4 mg new mint flavor variant.

NDA 18-612 S-037 (2mg)
NDA 20-066 S-019 (4mg)
These supplemental New Drug Applications (sNDA) are being submitted to acquire Over-the-Counter (OTC) marketing approval for a mint flavor Nicorette (nicotine polacrilex) 2 and 4 mg coated gum. This new formulation is also referred to by the sponsor as: Nicorette ---- mint Coated 2 and 4 mg gum throughout this application. The drug product contained in this supplemental application utilizes the original uncoated gum formulation as the gum core of the drug product. A xylitol-based
One *in vivo* bioequivalence study (Study No. NICSOS-9132-005) entitled, "Bioequivalence between Two New Nicotine Gums (2 and 4 mg) and Nicorette® Gum (2 and 4 mg) in an Open, Randomized, Crossover, Phase I Study in Healthy Smoking Volunteers" was included in this supplement. This study was designed to assess the bioequivalence between the original flavor 2 mg gum and the new mint flavor 2 mg coated variant, which is the subject of this sNDA. The study also compares the 4 mg original flavor gum and the 4 mg new mint flavor coated variant.

**Overview of the Studies**

Both of these studies used the same general design, in the appendix, the relevant summary pharmacokinetic parameters are reproduced in the following table for the uncoated 2mg gum:

**NICSOS-9132-003**

**Pharmacokinetic parameters (mean ± SD, median, min - max) – 2 mg gum**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Dose (mg)</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (ng/ml)</th>
<th>t&lt;sub&gt;max&lt;/sub&gt; (h)</th>
<th>AUC&lt;sub&gt;11-12h&lt;/sub&gt; (h*ng/ml)</th>
<th>Peak/Trough&lt;sup&gt;1&lt;/sup&gt; (%)</th>
<th>Swing&lt;sup&gt;1&lt;/sup&gt; (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New nicotine gum (n=30)</td>
<td>1.48 ± 0.18</td>
<td>18.1 ± 5.9</td>
<td>0.52 ± 0.10</td>
<td>16.6 ± 5.4</td>
<td>18 ± 6</td>
<td>20 ± 8</td>
</tr>
<tr>
<td>Nicorette&lt;sup&gt;®&lt;/sup&gt; gum (n=29)</td>
<td>1.32 ± 0.17</td>
<td>15.4 ± 5.2</td>
<td>0.44 ± 0.13</td>
<td>14.2 ± 4.7</td>
<td>17 ± 7</td>
<td>19 ± 8</td>
</tr>
</tbody>
</table>

1) last dosing interval

The equivalent data for the uncoated 4mg product is reproduced below;

**NICSOS-9132-003**

**Pharmacokinetic parameters (mean ± SD, median, min - max) – 4 mg gum**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Dose (mg)</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (ng/ml)</th>
<th>t&lt;sub&gt;max&lt;/sub&gt; (h)</th>
<th>AUC&lt;sub&gt;1&lt;/sub&gt; (h*ng/ml)</th>
<th>AUC&lt;sub&gt;∞&lt;/sub&gt; (h*ng/ml)</th>
<th>t&lt;sub&gt;50&lt;/sub&gt; (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New nicotine gum (n=30)</td>
<td>3.05 ± 0.38</td>
<td>9.8 ± 2.7</td>
<td>0.67 ± 0.27</td>
<td>26.1 ± 8.1</td>
<td>31.7 ± 10.0</td>
<td>2.77 ± 0.83</td>
</tr>
<tr>
<td>Nicorette&lt;sup&gt;®&lt;/sup&gt; gum (n=31)</td>
<td>2.87 ± 0.30</td>
<td>8.4 ± 2.5</td>
<td>0.64 ± 0.23</td>
<td>22.7 ± 8.8</td>
<td>28.7 ± 11.1</td>
<td>2.85 ± 0.89</td>
</tr>
</tbody>
</table>

While the data is fairly comparable within dose strengths, the variability in the amount of nicotine extracted ranges from __________ mg. These values barely approach the labeled 4mg amount, suggesting that, the extraction of nicotine from either dosage strength is less than the labeled amount and is dependent upon the physical act of chewing.
In a likewise manner the bioavailability data from the -005 study is reproduced below:

NICSOS-9132-005 (Coated Gum)

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Dose(^1) (mg)</th>
<th>(C_{max,1-12h}) (ng/ml)</th>
<th>(t_{max}) (^1) (h)</th>
<th>(AUC_{1-12h}) (h*ng/ml)</th>
<th>Peak/through(^2) (%)</th>
<th>Swing(^2) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New nicotine gum</td>
<td>1.40 ± 0.23</td>
<td>14.3 ± 3.6</td>
<td>0.55 ± 0.16</td>
<td>12.9 ± 3.4</td>
<td>23 ± 9</td>
<td>27 ± 12</td>
</tr>
<tr>
<td>(n=22)</td>
<td>(0.82-1.72)</td>
<td>(8.1 - 21.9)</td>
<td>(0.3 - 0.8)</td>
<td>(6.9 - 20.4)</td>
<td>(6 - 42)</td>
<td>(6 - 57)</td>
</tr>
<tr>
<td>Nicorette(^a) gum</td>
<td>1.26 ± 0.21</td>
<td>12.6 ± 3.1</td>
<td>0.45 ± 0.11</td>
<td>11.4 ± 2.9</td>
<td>20 ± 8</td>
<td>23 ± 10</td>
</tr>
<tr>
<td>(n=22)</td>
<td>1.25</td>
<td>12.0</td>
<td>0.50</td>
<td>11.2</td>
<td>18</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>(0.69-1.63)</td>
<td>(6.2 - 18.3)</td>
<td>(0.2 - 0.7)</td>
<td>(5.2 - 17.1)</td>
<td>(9 - 38)</td>
<td>(9 - 48)</td>
</tr>
</tbody>
</table>

\(^1\) n=27, \(^2\) last dosing interval

NICSOS-9132-005 Coated Gum

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Dose(^1) (mg)</th>
<th>(C_{max}) (ng/ml)</th>
<th>(t_{max}) (h)</th>
<th>(AUC_t) (h*ng/ml)</th>
<th>(AUC_{\infty}) (h*ng/ml)</th>
<th>(t_{1/2}) (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New nicotine gum</td>
<td>3.01 ± 0.36</td>
<td>9.6 ± 3.0</td>
<td>0.78 ± 0.29</td>
<td>31.0 ± 11.0</td>
<td>31.6 ± 9.8</td>
<td>2.53 ± 0.72</td>
</tr>
<tr>
<td>(n=24)</td>
<td>3.02</td>
<td>9.7</td>
<td>0.75</td>
<td>30.0</td>
<td>(16.4 - 47.1)</td>
<td>(1.2 - 4.2)</td>
</tr>
<tr>
<td></td>
<td>(2.01-3.66)</td>
<td>(4.9 - 15.9)</td>
<td>(0.3 - 1.5)</td>
<td>(12.8 - 49.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicorette(^a) gum</td>
<td>2.85 ± 0.31</td>
<td>8.4 ± 2.4</td>
<td>0.66 ± 0.21</td>
<td>28.6 ± 9.9</td>
<td>29.1</td>
<td>2.84 ± 1.20</td>
</tr>
<tr>
<td>(n=24)</td>
<td>2.87</td>
<td>8.1</td>
<td>0.75</td>
<td>29.1</td>
<td>(12.7 - 50.8)</td>
<td>2.76</td>
</tr>
<tr>
<td></td>
<td>(2.11-3.38)</td>
<td>(5.4 - 16.2)</td>
<td>(0.3 - 1.0)</td>
<td>(11.2 - 54.1)</td>
<td></td>
<td>(1.2 - 6.1)</td>
</tr>
</tbody>
</table>

\(^1\) n=30, \(^a\) Licitin

Bioequivalence

In order to demonstrate bioequivalence between the two formulations and two strengths, the sponsor conducted in vivo bioequivalence trials in healthy adult smokers. From the collected pk data 90% confidence intervals were constructed for assessment of bioequivalence between the products and within strengths.

<table>
<thead>
<tr>
<th></th>
<th>NICSOS-9132-003</th>
<th>NICSOS-9132-005</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>UNCOATED</td>
<td>COATED</td>
</tr>
<tr>
<td></td>
<td>2mg</td>
<td>4mg</td>
</tr>
<tr>
<td>AUCt</td>
<td>1.13-1.29*</td>
<td>0.96-1.19</td>
</tr>
<tr>
<td>AUCinf</td>
<td>1.10-1.23</td>
<td>0.98-1.17</td>
</tr>
<tr>
<td>Cmax</td>
<td>1.12-1.22</td>
<td>1.12-1.28*</td>
</tr>
<tr>
<td>AUC (MD)**</td>
<td>1.11-1.22</td>
<td>1.07-1.19</td>
</tr>
</tbody>
</table>

\*Exceeds 90% C.I. acceptance criteria of 80-125%

** AUC (MD)-Area Under the Curve Multiple Dose (last dosing interval)

In the “003” trial the 4mg product was outside the acceptable bioequivalence range for both AUC and Cmax. To address this issue the sponsor has proposed an alternative
analysis based on the actual delivered doses of nicotine, determined from residual gum analysis.

**Residual Nicotine Analysis**
One of the difficulties in doing bioequivalency trials with gum products is that dose is dependent upon the force and rate of chewing. In a crossover trial the amount of drug released can vary significantly. In order to correct for this the sponsor collected the chewed gum from this trial and did an extraction to determine the residual amount of nicotine released by chewing. The results of the residual analysis for this trial “-003” are contained in the table below:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose #</th>
<th>Mean</th>
<th>SD</th>
<th>Median</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 mg New nicotine gum</td>
<td>1</td>
<td>1.47</td>
<td>0.18</td>
<td>1.51</td>
<td></td>
</tr>
<tr>
<td>2 mg New nicotine gum</td>
<td>12</td>
<td>1.48</td>
<td>0.18</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td>2 mg Nicorette gum</td>
<td>1</td>
<td>1.30</td>
<td>0.18</td>
<td>1.33</td>
<td></td>
</tr>
<tr>
<td>2 mg Nicorette gum</td>
<td>12</td>
<td>1.33</td>
<td>0.17</td>
<td>1.35</td>
<td></td>
</tr>
<tr>
<td>4 mg New nicotine gum</td>
<td>1</td>
<td>3.05</td>
<td>0.38</td>
<td>3.13</td>
<td></td>
</tr>
<tr>
<td>4 mg Nicorette gum</td>
<td>1</td>
<td>2.87</td>
<td>0.30</td>
<td>2.87</td>
<td></td>
</tr>
</tbody>
</table>

From the collected gum from this trial one can see that the mean and median difference (current formulation – new formulation) in the extracted amount of nicotine was 0.18mg and 0.26mg respectively.

Although a numerically small difference, the sponsor then took this data and recalculated the pk parameters based on the actual delivered amounts of nicotine, and constructed new 90% confidence intervals.

**90% Confidence Intervals based on Residual Nicotine Analysis**

<table>
<thead>
<tr>
<th>NICSOS-9132-003</th>
<th>AUCt</th>
<th>AUCt (MD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2mg</td>
<td>1.07-1.21</td>
<td>1.01-1.10</td>
</tr>
<tr>
<td>4mg</td>
<td>1.04-1.15</td>
<td>1.01-1.10</td>
</tr>
</tbody>
</table>

This “dose delivered correction” is an unusual way of assessing relative bioavailability and bioequivalence. However, most dosage forms, ie. tablets, capsules, suspensions, etc. are not dependent on direct physical action on the dosage form for drug release. That is drug release is normally a passive process and not an active one. In the past because of this variability in drug release the Agency has encouraged the sponsor to use the “chewing machine” as a release rate tester. This is an automated device that, similar to a dissolution apparatus, has a number of stations submerged in a suitable media that
simulates the chewing action of teeth with porcelain disks. While not a direct simulation of the mouth and chewing per se, it does share similarities with in vitro dissolution apparatuses in that it is reproducible and can be calibrated as to speed and force.

Given the difficulties in obtaining re-producible release characteristics, as seen in these studies, it is the Agency's opinion that in vivo bioequivalency testing is not the preferred mechanism for approval of these minor formulation changes. Instead the Agency recommends that repeat testing with the in vitro chewing machine be used as it can provide reproducible conditions (i.e. control over the force and rate of chewing) that cannot be achieved in vivo.

**Recommendation**
Because of the results of the in vivo biostudies, the Agency has a split recommendation:

**NDA 18-612 S-037 (2mg) and NDA 20-066 S-019 (4mg)-** these supplements for the mint flavored coated nicotine gum are acceptable from a Clinical Pharmacology/Biopharmaceutics standpoint as they were able to establish in vivo bioequivalence between the current and re-formulated products.

**NDA 18-612 S-034 (2mg) and NDA 20-066 S-016 (4mg)-** these supplements for the mint flavored uncoated nicotine gum are not acceptable as the sponsor has failed to demonstrate in vivo bioequivalence, which is the only comparative data submitted for this product. It is the Agency's position that this failure of bioequivalence is due to the difficulties in establishing equivalent chewing patterns between the current and re-formulated products as a result of varying amounts of nicotine extracted under the test conditions. Rather than requiring a new in vivo biostudy, the Agency recommends that the sponsor demonstrate in vitro bioequivalence using the gum release rate tester, otherwise known as the "chewing machine". An in vitro apparatus such as this can provide both a consistent chewing force and rate of chewing that cannot be achieved readily in vivo and would thus be more reproducible, and allow for the comparison of products in a standardized manner.

Dennis Bashaw, Pharm.D.
PK Review Team Leader
for HFD-540/550/560
DPE-III (HFD-880)

Secondary Review: Arzu Selen, Ph.D., Deputy Director, DPE-III
Study # NICSOS-9132-003

Study Title: *Bioequivalence Between Two New Nicotine Gums (2 and 4 mg) and Nicorette® Gum (2 and 4 mg) In an Open, Randomized, Crossover, Phase I Study in Healthy Smoking Volunteers*

Objectives: This study was designed to assess the bioequivalence between the original flavor 2 mg gum and the new mint flavor 2 mg variant, under multiple dose conditions. The study also compares the 4 mg original flavor gum and the 4 mg new mint flavor variant following a single dose.

Study Design: Open-label, single dose (4 mg) and multiple-dose (2 mg), 2x2-way, randomized, cross-over study in healthy adult smokers.

Treatments:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Form</th>
<th>Strength</th>
<th>Appearance</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>New nicotine gum</td>
<td>Chewing gum</td>
<td>4 mg</td>
<td>square, uncoloured</td>
<td>14 x 14 x 5 mm</td>
</tr>
<tr>
<td>New nicotine gum</td>
<td>Chewing gum</td>
<td>2 mg</td>
<td>square, uncoloured</td>
<td>14 x 14 x 5 mm</td>
</tr>
<tr>
<td>Nicorette® nicotine gum</td>
<td>Chewing gum</td>
<td>4 mg</td>
<td>square, yellow</td>
<td>14 x 14 x 5 mm</td>
</tr>
<tr>
<td>Nicorette® nicotine gum</td>
<td>Chewing gum</td>
<td>2 mg</td>
<td>square, uncoloured</td>
<td>14 x 14 x 5 mm</td>
</tr>
</tbody>
</table>

Procedures
A total of 32 healthy smokers (17 male, 15 female) were enrolled in the study. One subject withdrew before start of study. Three subjects withdrew for reasons not related to the study after the third session. One subject was excluded from the analysis due to nicotine baseline concentration >5 ng/ml. Thus 30 subjects on 4 mg (single-dose comparison) and 28 subjects on 2 mg (multipledose comparison) were analyzed.

Twelve repeated doses (1 hour apart) of either new mint or original flavor were administered for the 2 mg gum and one dose of either new mint or original flavor for the 4 mg gum. Upon completion of each phase the subjects were washed out for a week before being crossed over to the other treatment.

Blood sampling for determination of nicotine were drawn pre-dose and at 5, 10, 15, 20, 30, 45 minutes, 1, 1.25 (1 hour 15 minutes), 1.5, 2, 3, 4, 6, 8 and 10 hours after administration of treatments A and B. The sampling times after treatments C and D were before each dose and at 10, 20, 30, 40, 50 minutes and 1 hour after the last administration. The exact time points for sampling were recorded. Time deviations of 1 minute or more from the planned sampling time were recorded.

The blood samples (5 ml) were collected in heparinized tubes. The plasma was then separated by centrifugation at 1000g for 10 minutes at +4°C. The plasma was then transported, in frozen condition (-20°) to Analytical R&D, Pharmacia AB, Consumer Healthcare, Helsingborg, Sweden, where they were analyzed for nicotine and cotinine (the primary metabolite of nicotine).
Results

Pharmacokinetic parameters (mean ± SD, median, min - max) . 2 mg gum

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Dose (mg)</th>
<th>Cmax (mg/ml)</th>
<th>tmax (h)</th>
<th>(\Delta \text{UC}11-12)h ((\mu\text{g}\cdot\text{mg}^{-1}))</th>
<th>Peak/</th>
<th>Swing (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New nicotine gum (n=50)</td>
<td>1.48 ± 0.10</td>
<td>18.1 ± 5.9</td>
<td>0.52 ± 0.10</td>
<td>16.6 ± 5.4</td>
<td>18 ± 6</td>
<td>20 ± 8</td>
</tr>
<tr>
<td></td>
<td>(0.65-1.81)</td>
<td>(8.4-33.6)</td>
<td>(0.33-0.67)</td>
<td>(5.6-29.9)</td>
<td>(7.31)</td>
<td>(7.37)</td>
</tr>
<tr>
<td>Nicorette gum (n=20)</td>
<td>1.32 ± 0.17</td>
<td>15.4 ± 5.2</td>
<td>0.44 ± 0.13</td>
<td>14.2 ± 4.7</td>
<td>17 ± 7</td>
<td>19 ± 8</td>
</tr>
<tr>
<td></td>
<td>(0.65-1.81)</td>
<td>(8.5-30.1)</td>
<td>(0.17-0.67)</td>
<td>(6.0-25.5)</td>
<td>(6.33)</td>
<td>(6.38)</td>
</tr>
</tbody>
</table>

\(^1\text{Intake dosage interval.}\)

Figure 4. Mean nicotine plasma concentrations after once hourly administration of 2 mg gums

![Graph: Mean nicotine plasma concentrations after once hourly administration of 2mg gums](image)

Figure 5. Individual nicotine plasma concentration-time curves (New nicotine gum 2 mg)

![Graph: Individual nicotine plasma concentration-time curves](image)
Figure 6. Individual nicotine plasma concentration-time curves
(Nicorette® gum 2 mg)
Nicotine plasma concentrations after once hourly administration of Nicorette gum 2 mg

Pharmacokinetic parameters (mean ± SD, median, min - max) . 4 mg gum

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Dose (mg)</th>
<th>Cmax (ng/ml)</th>
<th>tmax (h)</th>
<th>AUCt (h*ng/ml)</th>
<th>AUC0 (h*ng/ml)</th>
<th>t1/2 (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New nicotine gum (n=30)</td>
<td>3.13 (1.90-3.74)</td>
<td>9.2 (5.9-17.7)</td>
<td>0.50 (0.33)</td>
<td>24.9 (11.8)</td>
<td>29.4 (15.8)</td>
<td>2.90 (1.33)</td>
</tr>
<tr>
<td>Nicorette gum (n=31)</td>
<td>2.87 (2.20-3.39)</td>
<td>7.9 (4.9-17.7)</td>
<td>0.50 (0.33)</td>
<td>22.4 (10.2)</td>
<td>27.0 (12.7)</td>
<td>2.88 (1.34)</td>
</tr>
</tbody>
</table>
Figure 1. Mean nicotine plasma concentrations after single dose administration of 4 mg gum

Figure 2. Individual nicotine plasma concentration-time curves (New nicotine gum 4 mg)

Figure 3. Individual nicotine plasma concentration-time curves (Nicorette gum 4 mg)
Table 4. Amount of nicotine (mg) released during chewing

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose #</th>
<th>Mean</th>
<th>SD</th>
<th>Median</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 mg New nicotine gum</td>
<td>1</td>
<td>1.47</td>
<td>0.18</td>
<td>1.51</td>
<td></td>
</tr>
<tr>
<td>2 mg New nicotine gum</td>
<td>12</td>
<td>1.48</td>
<td>0.18</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td>2 mg Nicorette® gum</td>
<td>1</td>
<td>1.30</td>
<td>0.18</td>
<td>1.33</td>
<td></td>
</tr>
<tr>
<td>2 mg Nicorette® gum</td>
<td>12</td>
<td>1.33</td>
<td>0.17</td>
<td>1.35</td>
<td></td>
</tr>
<tr>
<td>4 mg New nicotine gum</td>
<td>1</td>
<td>3.05</td>
<td>0.38</td>
<td>3.13</td>
<td></td>
</tr>
<tr>
<td>4 mg Nicorette® gum</td>
<td>1</td>
<td>2.87</td>
<td>0.30</td>
<td>2.87</td>
<td></td>
</tr>
</tbody>
</table>

Table 5. Geometric mean and 90% confidence intervals for ratio New nicotine gum/Nicorette® gum

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Treatment</th>
<th>4 mg</th>
<th>2 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td></td>
<td>1.20 (1.12 - 1.28)</td>
<td>1.17 (1.12 - 1.22)</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;T&lt;/sub&gt;</td>
<td></td>
<td>1.21 (1.13 - 1.29)</td>
<td></td>
</tr>
<tr>
<td>AUC&lt;sub&gt;∞&lt;/sub&gt;</td>
<td></td>
<td>1.16 (1.10 - 1.23)</td>
<td></td>
</tr>
<tr>
<td>AUC&lt;sub&gt;11-12h&lt;/sub&gt;</td>
<td></td>
<td>1.16 (1.11 - 1.22)</td>
<td></td>
</tr>
</tbody>
</table>

Table 6. Geometric mean and 90% confidence intervals for ratio New nicotine gum/Nicorette® gum after correction for dose

<table>
<thead>
<tr>
<th>Parameter (corrected for dose)</th>
<th>Treatment</th>
<th>4 mg</th>
<th>2 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td></td>
<td>1.13 (1.06 - 1.20)</td>
<td>1.05 (1.01 - 1.10)</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;T&lt;/sub&gt;</td>
<td></td>
<td>1.13 (1.07 - 1.21)</td>
<td></td>
</tr>
<tr>
<td>AUC&lt;sub&gt;∞&lt;/sub&gt;</td>
<td></td>
<td>1.09 (1.04 - 1.15)</td>
<td></td>
</tr>
<tr>
<td>AUC&lt;sub&gt;11-12h&lt;/sub&gt;</td>
<td></td>
<td>1.05 (1.01 - 1.10)</td>
<td></td>
</tr>
</tbody>
</table>
Study # NICSOS-9132-005

Study Title: *Bioequivalence Between Two New Nicotine Gums (2 and 4 mg) and Nicorette Gum (2 and 4 mg) In an Open, Randomized, Crossover, Phase I Study in Healthy Smoking Volunteers*

Objectives: This study was designed to assess the bioequivalence between the original flavor 2 mg gum and the new mint flavor 2 mg variant, under multiple dose conditions. The study also compares the 4 mg original flavor gum and the 4 mg new mint flavor variant following a single dose.

Study Design: Open-label, single dose (4 mg) and multiple-dose (2 mg), 2x2-way, randomized, cross-over study in healthy adult smokers.

Treatments:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Drug</th>
<th>Dose</th>
<th>Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>New nicotine gum</td>
<td>4 mg</td>
<td>single-dose</td>
</tr>
<tr>
<td>B</td>
<td>Nicorette™ nicotine gum</td>
<td>4 mg</td>
<td>single-dose</td>
</tr>
<tr>
<td>C</td>
<td>New nicotine gum</td>
<td>12 mg</td>
<td>multiple-dose</td>
</tr>
<tr>
<td>D</td>
<td>Nicorette™ nicotine gum</td>
<td>12 mg</td>
<td>multiple-dose</td>
</tr>
</tbody>
</table>

Procedures
A total of 32 healthy smokers (15 male, 17 female) were enrolled in the study. Five subjects withdrew before completion of study. In the single dose treatment six subjects were excluded from the efficacy analysis due to nicotine baseline plasma concentrations >5 ng/ml. In the multiple dose treatment five subjects were excluded from the efficacy analysis due to nicotine baseline plasma.

Twelve repeated doses (administered 1 hour apart) of either new mint or original flavor were administered for the 2 mg gum and one dose of either new mint or original flavor for the 4 mg gum. Upon completion of each phase the subjects were washed out for a week before being crossed over to the other treatment.

Blood sampling for determination of nicotine were drawn pre-dose and at 5, 10, 15, 20, 30, 45 minutes, 1, 1.25 (1 hour 15 minutes), 1.5, 2, 3, 4, 6, 8 and 10 hours after the administration of treatments A and B. The sampling times after treatments C and D were before each dose and at 10, 20, 30, 40, 50 minutes and 1 hour after the last administration. The exact time points for sampling were recorded. Time deviations of 1 minute or more from the planned sampling time were recorded.

The blood samples (5 ml) were collected in heparinized tubes. The plasma was then separated by centrifugation at 1000g for 10 minutes at +4°C. The plasma was then transported, in frozen condition (-20°) to Analytical R&D, Pharmacia AB, Consumer Healthcare, Helsingborg, Sweden., where they were analyzed for nicotine and cotinine (the primary metabolite of nicotine).
Results

Pharmacokinetic parameters (mean ± SD, median, min - max) of 4 mg gum

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Dose¹ (mg)</th>
<th>Cmax (ng/ml)</th>
<th>tmax (h)</th>
<th>AUCr (h*ng/ml)</th>
<th>AUC∞ (h*ng/ml)</th>
<th>t½ (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New nicotine coated gum (n=24)</td>
<td>3.01 ± 0.36 (9.6 ± 3.0)</td>
<td>0.78 ± 0.20 (0.75)</td>
<td>31.0 ± 11.0 (30.0 - 12.8)</td>
<td>31.6 ± 8.8 (31.0 - 16.4)</td>
<td>2.53 ± 0.72 (2.6 - 1.2)</td>
<td></td>
</tr>
<tr>
<td>Nicorette gum (n=24)</td>
<td>2.85 ± 0.31 (8.4 ± 2.4)</td>
<td>0.66 ± 0.21 (0.75)</td>
<td>28.6 ± 9.9 (29.1 - 11.2)</td>
<td>29.1 ± 8.5 (28.0 - 12.7)</td>
<td>2.84 ± 1.20 (2.76 - 1.2)</td>
<td></td>
</tr>
</tbody>
</table>

¹ n=30

Appears this way on original
Figure 2. Individual Nicotine Plasma Concentration-time Curves (New Nicotine Gum 4 mg)

Figure 3. Individual Nicotine Plasma Concentration-time Curves (Nicorette® Gum 4 mg)
Pharmacokinetic parameters (mean ± SD, median, min - max). 2 mg gum

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Dose (^1) (mg)</th>
<th>Cmax, 11-12h (ng/ml)</th>
<th>t(\text{max}) (^2) (h)</th>
<th>AUC(\text{11-12h}) (h ng/ml)</th>
<th>Peak/ trough (^1) (%)</th>
<th>Swing (^2) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New nicotine coated</td>
<td>1.40 ± 0.23</td>
<td>14.2</td>
<td>0.55 ± 0.16</td>
<td>12.9 ± 3.4</td>
<td>23 ± 9</td>
<td>27 ± 12</td>
</tr>
<tr>
<td>gum (n=22)</td>
<td>1.40 (0.62-1.72)</td>
<td>(8.1-21.9)</td>
<td>0.50 (0.3-0.8)</td>
<td>(6.9 - 20.4)</td>
<td>(9 - 42)</td>
<td>(6 - 57)</td>
</tr>
<tr>
<td>Nicorette gum</td>
<td>1.28 ± 0.21</td>
<td>12.8 ± 3.9</td>
<td>0.45 ± 0.11</td>
<td>11.4 ± 2.9</td>
<td>20 ± 3</td>
<td>23 ± 10</td>
</tr>
<tr>
<td>(n=22)</td>
<td>1.25 (0.69-1.63)</td>
<td>(6.2 - 18.3)</td>
<td>0.50 (0.2-0.7)</td>
<td>(5.2 - 17.1)</td>
<td>(9 - 38)</td>
<td>(9 - 48)</td>
</tr>
</tbody>
</table>

\(^1\) n=27  \(^2\) fast dosing interval

Figure 4. Mean Nicotine Plasma Concentrations after Once Hourly Administration of 2 mg Gums
Figure 5. Individual Nicotine Plasma Concentration-time Curves (New Nicotine Gum 2 mg)

Figure 6. Individual Nicotine Plasma Concentration-time Curves (Nicorette® Gum 2 mg)
### Table 5. Amount of Nicotine (mg) Released during Chewing

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dose</th>
<th>Mean (gum)</th>
<th>SD</th>
<th>Median</th>
<th>Min-Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 mg New nicotine gum (n=29)</td>
<td>12</td>
<td>1.39</td>
<td>0.25</td>
<td>1.40</td>
<td></td>
</tr>
<tr>
<td>2 mg Nicorette® gum (n=28)</td>
<td>12</td>
<td>1.26</td>
<td>0.20</td>
<td>1.25</td>
<td></td>
</tr>
<tr>
<td>4 mg New nicotine gum (n=30)</td>
<td>1</td>
<td>2.01</td>
<td>0.36</td>
<td>3.02</td>
<td></td>
</tr>
<tr>
<td>4 mg Nicorette® gum (n=35)</td>
<td>1</td>
<td>2.85</td>
<td>0.30</td>
<td>2.87</td>
<td></td>
</tr>
</tbody>
</table>

### Table 6. Geometric Mean and 90% Confidence Intervals for Ratio New Nicotine Gum/ Nicorette® Gum

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Treatment</th>
<th>4 mg</th>
<th>2 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cavg/Cavg, 11-14h</td>
<td>1.1348 (1.0296 – 1.2503)</td>
<td>1.1363 (1.0720 – 1.2048)</td>
<td></td>
</tr>
<tr>
<td>AUC0-17h</td>
<td>1.0728 (0.9634 – 1.1947)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC0-1h</td>
<td>1.0771 (0.9662 – 1.1763)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC0-1:1h</td>
<td>1.2765 (1.0872 – 1.1914)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 7. Geometric Mean and 90% Confidence Intervals for Ratio New Nicotine Gum/ Nicorette® Gum after Correction for Content of Nicotine in the Gums

<table>
<thead>
<tr>
<th>Parameter (corrected for added amount of nicotine)</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cavg/Cavg, 11-14h</td>
<td>1.1617 (1.0512 – 1.2801)</td>
</tr>
<tr>
<td>AUC0-17h</td>
<td>1.0984 (0.9963 – 1.2252)</td>
</tr>
<tr>
<td>AUC0-1h</td>
<td>1.1027 (1.0026 – 1.2044)</td>
</tr>
<tr>
<td>AUC0-1:1h</td>
<td>1.2765 (1.0872 – 1.1914)</td>
</tr>
</tbody>
</table>
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Dennis Bashaw
4/1/04 08:10:22 PM
BIOPHARMACEUTICS

Arzu Selen
4/1/04 08:25:05 PM
BIOPHARMACEUTICS
APPLICATION NUMBER:
NDA 20-066 / S-016

CHEMISTRY REVIEW(S)
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Name and Address of Applicant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attention: Zinatara A. Manji, Associate, Regulatory Affairs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1500 Littleton Road, Parsippany, NJ 07054-3884</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Date of Submission Stamp PDUFA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11/26/03</td>
<td>12/2/03</td>
<td>4/2/04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Name of Drug:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicorette gum</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Nonproprietary Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicotine polacrilex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Supplement, PAS Provides for:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A new mint flavored Nicorette uncoated gum.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Amendment(s)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2/5/04, 3/1/04 &amp; 3/29/04</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Pharmacological Category</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking cessation aid</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. How Dispensed,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Related IND/NDA/DMF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMF 3835</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Dosage Form: Gums</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Potency(ies): 2 mg (18-612)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 mg (20-066)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14. Route of Administration: Oral, buccal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15. Comments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GlaxoSmithKline (GSK) requested to add a new mint flavored Nicorette uncoated gum. The active ingredient, Nicotine polacrilex, is a resin complex (polacrilex) containing , the same drug substance used in currently marketed Nicorette® gum formulations (Original, Mint and Orange flavors). The drug products, Nicorette® mint Uncoated 2 mg and 4mg gums are manufactured by Pharmacia at their facility in Cork, Ireland, which is a currently approved drug product manufacturing facility.

The 2 mg and 4 mg formulations, other than the flavoring, are similar to the currently approved Nicorette® gum formulations (Original, Mint and Orange flavors). Method of manufacture and quality control of the drug product were referenced to Pharmacia’s DMF #3835. Tests and acceptance criteria for drug product release and stability are provided. Satisfactory 18 months stability data with drug product stored in blister packaging at room temperature (25°C/60% RH) were submitted. New stability protocols that contained revised impurity limits per ICH 3B were proposed in the amendments of 3/1/04. The sponsor’s request for a 24 month expiration date is acceptable. The currently marketed Nicorette® gum formulations (Original, Mint and Orange flavors) carried 36 months expiration dates.


17. Name of the review chemist        Date
Bart Ho, Chemist                      March 19, 2004
APPEARS THIS WAY
ON ORIGINAL
Redacted 12 page(s) of trade secret and/or confidential commercial information from

CHEMISTRY REVIEW #1
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
Bartholomew Ho
3/30/04 11:38:40 AM
CHEMIST

John Smith
3/30/04 12:21:26 PM
CHEMIST
CONSULTATION

Date: April 2, 2004

To: Laura Shay
Project Manager, DOTCDP (HFD-560)

Through: Bob Rappaport, M.D.
Division Director, DACCADP

From: R. Daniel Mellon, Ph.D.
Supervisory Pharmacologist, DACCADP


Date of Submission: December 8, 2003

Date Response Requested (Priority): April 2, 2004 (Due April 2, 2004)

Background: GlaxoSmithKline (GSK) is developing a new flavor of Nicorette® gum that is softer and sweeter, in order to increase compliance and reach more of the smoking population who either will not or cannot use the currently marketed gum products due to either real or perceived dissatisfaction with the current tastes and flavors. The new formulation is called Nicorette® — mint Uncoated gum and was shown to be bioequivalent with the current marketed products.

Nicorette® gum comes in 2 mg and 4 mg strengths. According to the labeled directions for use, the maximum number of pieces you should chew a day is 24. Therefore, the
maximum daily nicotine exposure for the 2 mg and 4 mg gum would be 48 and 96 mg nicotine, respectively. Based upon this total daily intake (TDI), the qualification threshold for degradation products/impurities in the drug product would be set at 0.5% or 200 μg TDI, which ever is lower (ICHQ3BR). For the 2 mg gum product, 0.5% of 48 mg would be 240 μg TDI. For the 4 mg gum product, 0.5% of 96 mg would be 480 μg TDI. As such the ICH Q3BR specification for both drug products is 200 μg TDI.

GSK electronically submitted 2 chemistry supplements to their Nicorette® Gum NDAs as follows:

SCF034 Nicorette® 2 mg uncoated gum (NDA 18-612)
SCF016 Nicorette® 4 mg uncoated gum (NDA 20-066)

In addition, on March 1, 2004 and then again on March 29, 2004, GSK submitted amendments to these supplements (BC) that contains "finished product specifications"....these amendments are also in the EDR. The DMF for the drug substance, nicotine polacrilex (figure below) is held by Pharmacia and Upjohn Company, who authorized FDA to review DMF —— in support of the supplement.

Pharmacia and Upjohn Company consider the stability of the drug substance to be proprietary and thus that information is only in DMF ——. The drug product is manufactured by Pharmacia (DMF 3835) in the Helsingborg, Sweden facility. This site has already been approved for Nicorette® Original, Nicorette® Mint and Nicorette® Orange (2 and 4 mg).

The components of the —— Mint Formulation are listed in the sponsor's table below:
Redacted 6 page(s) of trade secret and/or confidential commercial information from 4/2/04 CONSULT
Myosmine is a minor alkaloid in tobacco. Until recently, human exposure to myosmine was thought to only occur via tobacco. However, myosmine can be detected in a wide variety of foods, including nuts and nut products, corn, rice, wheat flour, millet, potato, milk, cocoa, popcorn, tomato, carrot, pineapple, kiwi and apples. The levels of exposure to myosmine via common food staples could lead to an average dietary myosmine uptake of 475 \( \mu \)g/year (Tyroller et al., 2002).

![Myosmine](image)

**Acute Toxicology:** From the RTECs database

**LD\textsubscript{50}/LC\textsubscript{50} - LETHAL DOSE/CONC 50% KILL**

- **Rat**
  - \( \text{LD}_{50} \) ROUTE: Intraperitoneal; DOSE: 190 mg/kg
  - TOXIC EFFECTS:
    - Behavioral - Convulsions or effect on seizure threshold

  - \( \text{LD}_{50} \) ROUTE: Oral; DOSE: 1875 mg/kg
  - TOXIC EFFECTS:
    - Behavioral - Convulsions or effect on seizure threshold

**Genetic Toxicology:** Myosmine induced repairable DNA damage in a test with *Escherichia coli* pol A+/pol A- but was negative in the Ames test (Riebe et al., 1982). Myosmine did not enhance the frequency of sister chromatid exchanges in CHO cells (Riebe and Westphal, 1983). More recently myosmine was reported to test positive in the alkaline single cell microgel electrophoresis assay (Comet) to detect DNA single strand breaks (Kleinsasser et al., 2003).

Evidence exists that myosmine is metabolized to nornicotine. Nornicotine can be nitrosated under acidic conditions and a nitrate source, to nitrosonornicotine (NNN), a strong animal carcinogen and suspected human carcinogen (Wilp et al., 2002).

**Recommendation:**

At this time, the final specifications for --- mint uncoated Nicorette\textsuperscript{®} 2 mg and 4 mg gum products are acceptable from a pharmacology and toxicology perspective. However,
the sponsor should positive genetic toxicology reports in the literature and the potential conversion to nitrosocompounds.

Reference List


This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
R. Daniel Mellon
4/2/04 01:03:25 PM
PHARMACOLOGIST

Bob Rappaport
4/2/04 05:38:54 PM
MEDICAL OFFICER
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 20-066 / S-016

CORRESPONDENCE
April 6, 2004

Charles Ganley, M.D.
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Drug Evaluation V
Division of Over-the-Counter Drug Products, HFD-560
Document Control Room
9201 Corporate Blvd.
Rockville, MD 20850

Re: Supplemental New Drug Application NDA 20-066/S-016
Nicorette® (nicotine polacrilex) 4 mg Gum
Amendment #4: Complete Response to Approvable Letter (4/02/2004)

Dear Dr. Ganley:

Reference is made to NDA 20-066/S-016 dated November 26, 2003 for a new mint flavored Nicorette® (nicotine polacrilex) 4 mg uncoated gum. Reference is also made to an Approvable Letter sent by the Agency on April 2, 2004. This Amendment addresses the deficiencies noted in the referenced approvable letter.

An exact copy of the information provided herein is also contained in a submission of a Supplemental New Drug Application for Nicorette® 2 mg gum (NDA 18-612) sent under separate cover.

This submission has been organized into a folder-based structure in compliance with the guidance for providing regulatory submissions in electronic format (IT3 January 1999). The total size of the submission is approximately 1 MB, and is contained on one CDROM. It has been confirmed as virus free using Norton Antivirus software (version 7.61.930, scan engine 4.1.0.15, updated 1/21/2004) from Symantec.
Please contact the undersigned by phone at (973)-889-2322 or by fax at (973)-889-2501 with any questions relating to this Supplemental New Drug Application.

Sincerely,

[Signature]

Zinatara A. Manji
Associate, Regulatory Affairs

CC: Laura Shay
Regulatory Project Manager
March 12, 2004

Charles Ganley, M.D.
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Drug Evaluation V
Division of Over-the-Counter Drug Products, HFD-560
Document Control Room
9201 Corporate Blvd.
Rockville, MD 20850

Re: Supplemental New Drug Application NDA 20-066/S-016
Nicorette® (nicotine polacrilex) 4 mg Gum
Amendment #3
Revised Labeling – User’s Guide

Dear Dr. Ganley:

Reference is made to NDA 20-066/S-016 dated November 26, 2003 for a new mint flavored Nicorette® (nicotine polacrilex) 4 mg uncoated gum. Reference is also made to NDA 20-066/S-017 submitted December 23, 2003 to propose modifications to current labeling for Nicorette® 2 mg and 4 mg (Original, Mint and Orange) gum and the subsequent Amendment #1, submitted March 12, 2004.

In accordance with the Agency’s response to NDA 20-066/S-017, sent on February 24, 2004, the User’s Guide was revised and submitted in Amendment #1. In order to maintain consistency between these two supplements, enclosed please find an amended User’s Guide. The Agency’s changes to carton labeling, in the above referenced letter (S-017), will be reflected in the final printed labeling for this supplement (S-016).

An exact copy of the information provided herein is also contained in a submission of a Supplemental New Drug Application for Nicorette® 2 mg gum (NDA 18-612) sent under separate cover.

This submission has been organized into a folder-based structure in compliance with the guidance for providing regulatory submissions in electronic format (IT3 January 1999). The total size of the submission is approximately 1 MB, and is contained on one CDROM. It has been confirmed as virus free using Norton Antivirus software (version 7.61.930, scan engine 4.1.0.15, updated 3/18/2004) from Symantec.
Please contact the undersigned by phone at (973)-889-2322 or by fax at (973)-889-2501 with any questions relating to this Supplemental New Drug Application.

Sincerely,

Zinatara A. Manji
Associate, Regulatory Affairs

CC: Laura Shay
Regulatory Project Manager
March 1, 2004

Charles Ganley, M.D.
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Drug Evaluation V
Division of Over-the-Counter Drug Products, HFD-560
Document Control Room
9201 Corporate Blvd.
Rockville, MD 20850

Re: Supplemental New Drug Application NDA 20-066/S-016
Nicorette® (nicotine polacrilex) 4 mg Gum
Amendment #2
CMC: Revised Finished Product Specifications

Dear Dr. Ganley:

Reference is made to NDA 20-066/S-016 dated November 26, 2003 for a new mint flavored Nicorette® (nicotine polacrilex) 4 mg uncoated gum. Reference is also made to Item 4: Chemistry, Manufacturing and Controls in this supplemental application. This amendment reflects data generated from additional stability information. Stability data on nicotine related impurities and degradation products indicate that

- For convenience in review, we have republished the Methods Validation Package to incorporate these changes.

This submission has been organized into a folder-based structure in compliance with the guidance for providing regulatory submissions in electronic format (IT3 January 1999). The total size of the submission is approximately 17 MB, and is contained on one CDROM. It has been confirmed as virus free using Norton Antivirus software (version 7.61.930, scan engine 4.1.0.15, updated 1/21/2004) from Symantec.
Please contact the undersigned by phone at (973)-889-2322 or by fax at (973)-889-2501 with any questions relating to this Supplemental New Drug Application.

Sincerely,

Zinatara A. Manji  
Associate, Regulatory Affairs

CC: Laura Shay  
Regulatory Project Manager
NDA 20-066/S-016

PRIOR APPROVAL SUPPLEMENT

GlaxoSmithKline Consumer Healthcare
Attention: Zinatara A. Manji
Associate, Regulatory Affairs
1500 Littleton Road
Parsippany, NJ 07054-3884

Dear Ms. Manji:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Nicorette® 4mg (nicotine polacrilex) gum

NDA Number: 18-612

Supplement number: 034

Date of supplement: November 26, 2003

Date of receipt: December 2, 2003

This supplemental application proposes a new mint flavored uncoated gum.

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on January 31, 2004, in accordance with 21 CFR 314.101(a). If the application is filed, the goal date will be April 2, 2004.

All communications concerning this supplement should be addressed as follows:

U.S. Postal Service:
Center for Drug Evaluation and Research
Division of Over the Counter Drug Products, HFD-560
5600 Fishers Lane
Rockville, Maryland 20857
Courier/Overnight Mail:
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Over the Counter Drug Products, HFD-560
Attention: Document Room
9201 Corporate Blvd.
Rockville, Maryland 20850

If you have any questions, call Laura Shay, Regulatory Project Manager, at (301) 827-2274.

Sincerely yours,

[See appended electronic signature page]

David Hilfiker
Chief, Project Management Staff
Division of Over the Counter Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

------------------

David Hilfiker
12/23/03 02:39:47 PM